



For Animal Use Only

Reg. No. G3842 (Act 36 of 1947)

Feline Leukaemia Vaccine Killed Virus

For use by or under the control of a veterinarian only

INDICATIONS
 For the vaccination of healthy cats as an aid in preventing persistent viraemia and lymphoid tumours caused by feline leukaemia virus, and diseases associated with feline leukaemia virus infection.

STORAGE INSTRUCTIONS
 Store between 2 °C and 7 °C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

COMPOSITION
 At release, each single dose vial (1 ml) of LeukoCELL 2 contains an inactivated adjuvanted sub-unit feline leukaemia virus (Felv) vaccine containing all three Felv subgroup (A, B and C) antigens and feline oncornavirus associated cell membrane antigen (FOCMA) in a non-immunosuppressive form with a relative potency ≥ 1.20.


WARNINGS
 Vaccination is of no known therapeutic value in cats with existing feline leukaemia virus infection, nor will it alter the natural course of disease. The use of immunosuppressant drugs or procedures within one month of vaccination is contra-indicated. A protective immune response may not be elicited if animals are incubating an infectious disease; are malnourished or parasitized; are stressed due to shipment or environmental conditions; are otherwise immunocompromised; or the vaccine is not administered in accordance with label direction. Post-vaccination reactions have been observed in about 2 % of vaccinated cats. These included stinging on injection, transient listlessness, depression, and brief temperature elevations. Hypersensitivity evidenced by myxoedema and gastrointestinal distress (vomiting and bowel evacuation) occasionally has been reported. Post vaccination reactions have not been observed after the administration of an overdose of LeukoCELL 2. As with any vaccine, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy. Contains trace quantities of gentamicin as preservative. Keep out of reach of children, uninformed persons and animals. Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS
 No special precautions for use if the normal rules for vaccination are followed. Ensure vaccination equipment is clean and sterile before use and remains so during vaccination. **DIRECTIONS**
 Use only as directed. Only for use by or under the supervision of persons registered in terms of or authorized in terms of section 23 (1) (c) of the Veterinary and Para-Veterinary Professions Act (Act 19 of 1982). *General directions:* Shake well. Aseptically administer 1 ml subcutaneously. *Primary Vaccination:* Healthy cats 9 weeks of age or older should receive 2 doses administered 3-4 weeks apart. *Revaccination:* Annual revaccination with a single dose is recommended. Use entire content when first opened. Empty or partly-used vaccine vials should be incinerated or immersed in an approved disinfectant before disposal. There are no known interactions. *Use during pregnancy and lactation:* LeukoCELL 2 vaccination does not have any adverse effects on either pregnant queens or their kittens. **PRESENTATION**
 The product may be marketed in the following presentations: boxes containing 10, 25 or 50 vials.

Vaccine is supplied in 1 ml glass vials sealed with rubber stoppers and aluminium seals.

REGISTRATION HOLDER
 Zoetis South Africa (Pty) Ltd
 Co. Reg. No.: 2012/001825/07
 P.O. Box 783720, Sandton, 2146
 South Africa
 Tel.: (011) 245 3300 or 0860 ZOETIS (0860 963847)
 U.S. Veterinary License No. 190
 Zoetis Inc, 601 West Cornhusker Hwy,
 Lincoln, Nebraska 68521, USA
 The LeukoCELL and the Zoetis logo are registered trademarks.

Namibia: V10/24.2/1035 [NS2]



10/2016
50229600

Spine

Slegs vir Dieregebruik




Reg. Nr. G3842 (Wet 36 van 1947)

Kat Leukemie Entstof Dooie Virus

Slegs vir gebruik deur of onder die beheer van 'n veearts

INDIKASIES
 Vir inenting van gesonde katte as hulpmiddel in die voorkoming van hardnekkige viremie en limfoïed gewasse veroorsaak deur die kat leukemie virus en siektes wat met kat leukemie virus infeksie vereenselwig word.

BERGINGSAAWYSINGS
 Berg tussen 2 °C en 7 °C. Langdurige blootstelling aan hoër temperatuur mag die sterkte ongunstig beïnvloed. Moet nie bevries nie.

SAMESTELLING
 Tydens vrystelling, bevat elke enkel-dosis flessie (1 ml) LeukoCELL 2'n geïnaktiveerde, geadjuvanteerde sub-eenheid kat leukemie virus (Felv) entstof wat al drie Felv subgroep (A, B en C) antigene bevat asook kat oncornavirus geassosieerde sel membraan antigeen in 'n nie-immuunonderdrukkende vorm met 'n relatiewe sterkte ≥ 1.20.

WAARSKUWINGS
 Inenting is terapeuties van geen bekende waarde by katte met bestaande kat leukemie virus infeksie nie en sal ook nie die natuurlike verloop van die siekte wysig nie. Die gebruik van immuunonderdrukkende middels of prosedures binne een maand na inenting is teenaangewys. 'n Beskermende immuunreaksie mag dalk nie ontlok word indien diere 'n aansteeklike siekte inkubeer nie; ondervoed of geparasiteerd is; onder stres verkeer weens vervoer of omgewingsoorsake; andersins immuungekompromiteerd is; die vaksien nie volgens etiketaanwysings toegedien is nie. Na-inenting reaksies is opgemerk in ongeveer 2 % van katte wat ingeënt is. Dit sluit in branderigheid tydens inspuiting, tydelike lusteloosheid, depressie en kortstondige toename in temperatuur. Hipersensitieweit wat blyk uit miksedeem en gastrointestinale nood (braking en derm lediging) is soms aangemeld. Na-inenting reaksies is nie opgemerk nie na 'n oordosis van LeukoCELL 2. Soos met enige entstof, kan anafilakse na gebruik voorkom. Aanvanklike teenmiddel behandeling met epinefrien word aanbeveel en behoort opgevolg te word met toepaslike bystandsbehandeling. Bevat tekens van gentamisien as preserveermiddel. Hou buite bereik van kinders, oningeligte persone en diere. Alhoewel hierdie vaksien uitgebreide toetsing onder 'n groot verskeidenheid omstandighede ondergaan het, kan mislukking daarvan volg weens verskeie redes. Indien dit vermoed word, verkry veeartseny advies en verwittig die registrasiehouer.

VOORSORGMATREËLS
 Geen spesiale voorsorgmaatreëls word vereis indien normale reëls gevolg word vir inenting nie. Verseker dat toerusting vir inenting skoon en steriel is voor gebruik en dat dit so bly tydens inenting.

AANWYSINGS
 Gebruik slegs soos voorgeskryf. Slegs vir gebruik deur of onder toesig van persone wie geregistreer is of gemagtig is in terme van seksie 23 (1) (c) van die Veterinêre en Para-Veterinêre Beroepswet (Wet 19 van 1982). *Algemene aanwysings:* Skud deeglik. Dien 1 ml asepties onderhuid toe. *Primêre inenting:* Gesonde katte 9 weke of ouer behoort 2 dosisse 3-4 weke uitmekaar te ontvang. *Herinenting:* Jaarlikse herinenting met 'n enkel dosis word aanbeveel. Gebruik die totale inhoud wanneer dit oopgemaak is. Lê of gedeeltelik-gebruikte entstof flessies behoort verbrand te word of in 'n goedgekeurde ontsmettingsmiddel gedompel te word voor wegdoening. Daar is geen bekende interaksies nie. *Gebruik tydens dragtigheid en soging:* LeukoCELL 2 inenting het geen nuwe effekte op dragtige katte of hulle katjies nie.

AANBIEDING
 Hierdie produk kan bemark word in die volgende aanbiedings: houers wat 10, 25 of 50 flessies bevat. Die entstof word voorsien in 1 ml glas flessies geseël met rubber proppe en aluminium seëls.

REGISTRASIEHOUER
 Zoetis South Africa (Pty) Ltd
 Mpy. Reg. Nr.: 2012/001825/07
 Posbus 783720, Sandton, 2146
 Suid Afrika
 Tel.: (011) 245 3300 of 0860 ZOETIS (0860 963847)
 U.S. Veterinary License No. 190
 LeukoCELL en die Zoetis logo is geregistreerde handelsmerke.

Namibia: V10/24.2/1035 [NS2]



10/2016
50229600

Spine

Time/Date: 50229600.indd 1 1/23/17 1:54 PM

zoetis	Project No. 14366	Component Material No. 40014712	Country South Africa
	Artwork DIR No. 50229600	Description LeukoCELL 2	DIR Type/Description Z63/Insert
Dimensions 12" x 3" Folds to 3" x 3"	Drawing No. Z14-801602	FG Material No. 10006154	EDITOR'S COPY DATE: _____ GS: <input type="checkbox"/>
Colors: Black Dieline	PR	GS / ART REV (LCA) CHANGES OK	GS / ART REV (FA) CHANGES OK
Rev GA	4	GS G. Woods	GA S. Lewis/J. Disch

Document Approvals

Tad Kastl	Lincoln - Plant Coordinator 25-Jan-2017 16:41:05 GMT+0000
Stephanie Kuhn	South Africa - MRO Lead 26-Jan-2017 08:32:43 GMT+0000
Carolyn Hoy	Lincoln - Site QA 26-Jan-2017 11:51:09 GMT+0000
Sandra Frazee	Lincoln - Site QA 26-Jan-2017 13:40:32 GMT+0000
Stephanie Kuhn	South Africa - External Agency 26-Jan-2017 13:43:34 GMT+0000
Michele Brettmann	United States - External Agency 28-Feb-2017 18:51:12 GMT+0000